These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33369212)

  • 21. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation.
    Kremers RM; Wagenvoord RJ; Hemker HC
    Thromb Haemost; 2016 Apr; 115(4):869-70. PubMed ID: 26467386
    [No Abstract]   [Full Text] [Related]  

  • 23. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.
    Adelmann D; Wiegele M; Wohlgemuth RK; Koch S; Frantal S; Quehenberger P; Scharbert G; Kozek-Langenecker S; Schaden E
    Thromb Res; 2014 Oct; 134(4):918-23. PubMed ID: 25179518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of NOACs on Thrombin Generation Assay].
    Kawasugi K
    Rinsho Byori; 2014 Oct; 62(10):965-9. PubMed ID: 27526542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the analyzer ST Genesia.
    Modi Omasombo N; Demulder A; Rozen L
    Ann Biol Clin (Paris); 2022 Mar; 80(2):148-155. PubMed ID: 35766075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
    Wong PC; White A; Luettgen J
    Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombin generation in children using ThromboScreen reagent kit with ST Genesia-A pilot study.
    Gassiot S; Ruiz-Llobet A; Suleman W; Sarrate E; Berrueco R
    Int J Lab Hematol; 2021 Dec; 43(6):1612-1619. PubMed ID: 34323010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring of heparin therapy beyond the anti-Xa activity assay: Evaluation of a thrombin generation assay.
    Vermeiren P; Vandevelde A; Peperstraete H; Devreese KMJ
    Int J Lab Hematol; 2022 Aug; 44(4):785-795. PubMed ID: 35438827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Not Available].
    Strandberg K
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512144
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
    Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
    J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.
    Boissier E; Senage T; Babuty A; Gouin-Thibault I; Rozec B; Roussel JC; Sigaud M; Ternisien C; Trossaert M; Fouassier M; Lakhal K
    Anesth Analg; 2021 Mar; 132(3):707-716. PubMed ID: 32833716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
    J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia.
    Dix C; McFadyen JD; Tran HA
    Thromb Res; 2024 May; 237():148-153. PubMed ID: 38603817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of centrifugation on thrombin generation in healthy subjects and in patients treated with direct oral anticoagulants.
    Hardy M; Dellanoce C; Douxfils J; Carlo A; Lessire S; Bouvy C; Testa S; Mullier F
    Int J Lab Hematol; 2021 Dec; 43(6):1585-1592. PubMed ID: 34252264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of apixaban anti-factor Xa assay and impact of body weight.
    Wasan SM; Feland N; Grant R; Aston CE
    Thromb Res; 2019 Oct; 182():51-55. PubMed ID: 31450008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.